A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

W Kielbasa, DL Helton - Cephalalgia, 2019 - journals.sagepub.com
Purpose To review pharmacokinetic and pharmacodynamic characteristics of antibodies that
bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies …

The story of EGFR: from signaling pathways to a potent anticancer target

S Ramani, S Samant, SM Manohar - Future Medicinal Chemistry, 2022 - Taylor & Francis
EGFR is a member of the ERBB family. It plays a significant role in cellular processes such
as growth, survival and differentiation via the activation of various signaling pathways. EGFR …

Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology

G Bajaj, S Suryawanshi, A Roy… - British journal of clinical …, 2019 - Wiley Online Library
Aims The development of monoclonal antibodies (mAbs) requires an understanding of the
interindividual variability (IIV) in pharmacokinetics (PK) at the population level facilitated by …

Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans

D Ternant, N Azzopardi, W Raoul… - Clinical …, 2019 - Springer
Therapeutic antibodies are increasingly used to treat various diseases, including neoplasms
and chronic inflammatory diseases. Antibodies exhibit complex pharmacokinetic properties …

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized …

VL Stauffer, I Turner, P Kemmer, W Kielbasa… - The Journal of …, 2020 - Springer
Background Migraine clinical profile may change with age, making it necessary to verify that
migraine treatments are equally safe and effective in older patients. These analyses …

Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review

X Li, Z Song, Z Yi, J Qin, D Jiang… - Therapeutic …, 2024 - journals.sagepub.com
Background: Compared with anti-infective drugs, immunosuppressants and other fields, the
application of therapeutic drug monitoring (TDM) in oncology is somewhat limited. Objective …

Engineering antibodies with cancer‐associated binding sites

Y Tian, Y Pan, Y Zhang, F Wang, Z Wang - BMEMat, 2024 - Wiley Online Library
Cancer immunotherapy has appeared as a prospective therapeutic modality. Therapeutic
antibodies induced in an in vitro expression system act as “targeting missiles” against tumor …

EGFR 外显子20 插入突变: 研究现状与治疗新策略

T Mengwei, W Na, DOU Zhanjun… - Chinese Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
作为非小细胞肺癌(non-small cell lung cancer, NSCLC) 中重要的致癌驱动基因,
表皮生长因子受体外显子20 插入突变(epidermal growth factor receptor exon 20 insertion …

Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients

E Chigutsa, AJ Long, JE Wallin - CPT: Pharmacometrics & …, 2017 - Wiley Online Library
We sought to describe the exposure–response relationship of necitumumab efficacy in
squamous non‐small cell lung cancer patients and evaluate intrinsic and extrinsic patient …

EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies

T Mengwei, W Na, DOU Zhanjun, S Xia… - Zhongguo Fei Ai …, 2024 - search.proquest.com
作为非小细胞肺癌 (non-small cell lung cancer, NSCLC) 中重要的致癌驱动基因,
表皮生长因子受体外显子 20 插入突变 (epidermal growth factor receptor exon 20 insertion …